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1  | INTRODUC TION
Multiple myeloma (MM) accounts for roughly 1% of all cancers and 
approximately 10% of haematological malignancies worldwide.1 
Bone lesions are a hallmark of MM2; up to 95% of patients will 
develop osteolytic bone lesions at some point during their treat-
ment.2-4 These bone lesions are often associated with severe pain, 
nerve compression syndromes and skeletal- related events (SREs).3-5
By definition, SREs include pathologic fracture and spinal cord 
compression, as well as radiation or surgery to bone (which are surro-
gate markers for skeletal pain and fractures).5 SREs increase the risk 
of death,6 are often debilitating and result in severe pain; they can 
impact a patient’s ability to carry out daily activities and to work and 
reduce their quality of life.7,8 SREs are common in individuals with 
MM; it is estimated that up to 60% of patients will suffer a pathologic 
fracture during their treatment journey,2 resulting in pain, reduced 
 
Accepted: 26 January 2018
DOI: 10.1111/ejh.13044
O R I G I N A L  A R T I C L E
Healthcare resource utilisation associated with skeletal- related 
events in European patients with multiple myeloma: Results 
from a prospective, multinational, observational study
John Ashcroft1  | Ignacio Duran2 | Herbert Hoefeler3 | Vito Lorusso4 |  
Diana Lueftner5 | Marco Campioni6 | Michele Intorcia6 | Amit Bahl7
1Pinderfields General Hospital, Wakefield, 
UK
2Instituto de Biomedicina de Sevilla, IBiS/
Hospital Universitario Virgen del Rocío/
CSIC/Universidad de Sevilla, Sevilla, Spain
3Forschungszentrum Ruhr, Witten, Germany
4Instituto Oncologico, IRCCS, Bari, Italy
5Medical Department, Division of 
Hematology, Oncology and Tumor 
Immunology, Charité Campus Benjamin 
Franklin, Universitätsmedizin Berlin, Berlin, 
Germany
6Health Economics, Amgen (Europe) GmbH, 
Zug, Switzerland
7University Hospitals Bristol, Bristol, UK
Correspondence
John Ashcroft, Pinderfields General 
Hospital, Wakefield, UK.
Email: johnashcroft@doctors.org.uk
Funding information
Amgen (Europe) GmbH
Abstract
Objectives: Patients with multiple myeloma (MM) often experience debilitating 
skeletal- related events (SREs: pathologic fracture, radiation to bone [RB], surgery to 
bone [SB] or spinal cord compression [SCC]). This is the first comprehensive, pro-
spective, observational analysis of healthcare resource utilisation (HRU), indepen-
dently attributed to SREs by investigators, in patients with MM.
Methods:	Eligible	patients	had	lytic	bone	lesions,	life	expectancy	≥6	months,	Eastern	
Cooperative	Oncology	Group	performance	status	≤2	and	≥1	SRE	in	the	97	days	be-
fore enrolment. Data were collected retrospectively for 97 days before enrolment 
and prospectively for 18- 21 months.
Results: Altogether, 153 patients were enrolled from Germany, Italy, Spain and the 
United Kingdom. Of the 281 observed SREs, 36.7% required inpatient stays (mean dura-
tion: 20.6 days per SRE [standard deviation (SD): 22.9]). SB and SCC were the SREs most 
likely to require stays (72.3% and 50.0% of SREs, respectively); SCC required the longest 
mean (SD) stay per event (40.5 [40.8] days). Overall, 179 SREs required outpatient visits; 
this was most likely for RB (74.8%) and least likely for non- vertebral fracture (50.0%).
Conclusions: All SREs were associated with substantial HRU; therefore, preventing 
SREs in MM will reduce the economic and resource burden on healthcare systems.
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load- bearing capacity and, frequently, restricted movement.5 Spinal 
cord compression is a medical emergency that can lead to paralysis.5
In addition to the effect on patients’ well- being, SREs also place a 
significant burden on healthcare systems. Previous studies have shown 
that, in particular, surgery to bone is associated with long inpatient 
stays in patients with solid tumours or MM.3,9 Several retrospective 
studies in the United States of America (USA) and Europe that included 
patients with MM demonstrated increased healthcare resource utilisa-
tion (HRU) and/or costs associated with SREs.3,4,10-13 Although these 
data provide some insight into the impact that SREs have on HRU by 
these patients, they may be limited by the scope and completeness 
of the available HRU data and by the use of codes (clinical and/or ad-
ministrative) as proxies for diagnosis and resource use. Prospective 
data, collected from a broader European population, could provide 
more extensive, complete and robust information on the real- life use 
of healthcare resources in the treatment of SREs to better inform op-
timum approaches for patient management and healthcare planning.
A prospective, observational, multinational study was con-
ducted to evaluate the HRU associated with SREs in patients with 
bone lesions secondary to prostate, breast or lung cancer and MM 
in Canada, Germany, Italy, Spain, the United Kingdom (UK) and the 
USA. Data on the HRU associated with SREs in breast cancer, lung 
cancer and prostate cancer in the four European countries (Germany, 
Italy, Spain and the UK) have been previously reported.14-16 Here, we 
report the European data for patients with MM.
2  | METHODS
2.1 | Patients
The methods used in this study have been described previously.3 
Eligible patients were aged 18 years or older with bone lesions 
that were secondary to MM and had a life expectancy of at least 
6 months. Patients were required to have an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0- 2 and to have ex-
perienced at least one SRE in the 97 days before signing informed 
consent or up to 7 days afterwards.16 Patients were excluded from 
the study if they were enrolled in an investigational drug trial for 
treatment of bone lesions or prevention of SREs.
2.2 | Study design
This was a multicentre, prospective, observational study conducted 
in centres across Europe (Germany, Italy, Spain and the UK), Canada 
and the USA. Analysis by country and tumour type was prespeci-
fied in the protocol. This analysis reports only on data from the four 
European countries in patients with bone lesions secondary to MM. 
Enrolment began in 2008, and the data cut- off date for the final 
analysis was 31 May 2010.
Patient demographics and information on disease history were 
collected at enrolment. HRU data for each patient were collected 
retrospectively by chart review for all SREs occurring in the 97- day 
period before enrolment and prospectively for the duration of their 
involvement in the study. SREs were defined as pathologic fracture 
(either vertebral or non- vertebral), radiation to bone, surgery to bone 
or spinal cord compression, and events were recorded according to 
the results of physicians’ assessments as per their routine clinical 
practice. Full data collection occurred at 90- day, mandatory mile-
stones (calculated from the enrolment date), but with SRE- related 
HRU recorded as soon as the site was made aware of the SRE. The 
planned follow- up period was 18- 21 months. In the case of a patient 
who experienced more than one SRE in the 97 days preceding study 
entry, the index SRE was classified based on the following hierarchy: 
(i) spinal cord compression; (ii) surgery to bone; (iii) pathologic frac-
ture (vertebral or non- vertebral); and (iv) radiation to bone.
For patients who experienced multiple SREs at the same ana-
tomical site, HRU was attributed to the first SRE (ie, the index SRE) 
if subsequent events occurred within 21 days of the index event. If 
subsequent SREs occurred at a different anatomical site or occurred 
more than 21 days after the index event at the same anatomical site, 
the investigator decided to which SRE the HRU was attributed. HRU 
outcome measures included the following: number, duration and fa-
cility type of inpatient stays; number and facility type of outpatient 
visits; number of emergency department visits; number, duration 
and facility type of nursing home/long- term care facility stays; num-
ber of home health visits; and type of procedure.
2.3 | Statistical analysis
All analyses were descriptive and the HRU outcome measures were 
categorised by SRE type. For each of the HRU measures, the mean 
values (eg, number or duration of inpatient stay) for each SRE type 
were calculated by dividing the total HRU attributed to SREs by the 
total number of SREs of the same type. The mean duration of inpa-
tient stay per SRE was calculated as the total number of inpatient 
days divided by the total number of SREs that were associated with 
an inpatient stay; if an SRE resulted in multiple inpatient stays, the 
total duration of all inpatient stays was used.
Data on inpatient stays by facility type reported SREs with at least 
one inpatient stay within the facility type and SRE type. When an SRE 
required stays in more than one facility type, a stay was attributed to 
each facility type. If an SRE required multiple inpatient stays within 
one facility type, the total duration of inpatient stays was counted.
If radiation or surgery to bone was carried out as a result of 
another SRE (ie, treatment of a primary SRE, such as pathologic 
fracture), the investigator had the option of attributing HRU to the 
primary SRE. SREs determined to be secondary to a primary SRE 
were excluded from the analysis, as reported previously.16
3  | RESULTS
3.1 | Study population
At the time of the final analysis, 153 patients with MM who met the 
eligibility criteria were enrolled across the four European countries. 
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Mean (standard deviation; SD) length of follow- up ranged from 6.0 
(5.0) to 9.6 (6.0) months, and median follow- up ranged from 5.5 to 
10.8 months (Table 1). While generally consistent, there was some 
variation in baseline characteristics and disease history across the 
four countries (Table 1); for example, there were fewer women en-
rolled in the UK (12.0%) than in the other countries (range, 41.2%- 
56.4%). There was a higher proportion of patients with an ECOG 
performance status of 0 in Germany (35.3%) than in the other coun-
tries (range, 10.3%- 24.0%), and a lower proportion of patients with 
ECOG performance status of 2 (15.7% vs 38.5%- 50.0%). Patients in 
Germany and the UK were more likely to receive bisphosphonates 
prior to treatment on study (82.4% and 88.0% of patients, respec-
tively) compared with Italy or Spain (48.7% and 50.0% of patients, re-
spectively). The median time from bone lesion detection to enrolment 
was shorter in Spain (1.6 months) than in the other countries (range, 
3.7- 5.8 months). A total of 42 patients (27.5%) discontinued the study 
before the primary data analysis cut- off date (Germany: 20/51, 39.2% 
[14 owing to death, 4 lost to follow- up, 2 other]; Italy: 7/39, 17.9% [5 
owing to death, 2 lost to follow- up]; Spain: 7/38, 18.4% [5 owing to 
death, 2 lost to follow- up]; UK: 8/25, 32% [all owing to death]).
3.2 | Skeletal- related events
Eligible patients experienced a total of 321 SREs. Analysis of the raw 
SRE data (which included SREs secondary to primary SREs and was 
ultimately excluded from the final HRU analysis) showed that the 
event rate in this population of patients (who had all experienced an 
SRE) was consistent across Germany, Italy and Spain (2.2, 1.9 and 
2.2 SREs per patient- year, respectively), but slightly higher in the UK 
(2.6 SREs per patient- year). In total, 281 of the 321 SREs were suit-
able for inclusion in the HRU analysis (Figure 1). Overall, radiation to 
bone (38.1%) and pathologic fracture (34.5%) were the most common 
SREs; spinal cord compression was the least common, accounting for 
10.7% of SREs.
Characteristic Germany (N = 51) Italy (N = 39) Spain (N = 38) UK (N = 25)
Follow- up time (mo)
Mean (SD) 9.6 (6.0) 9.3 (5.5) 8.7 (6.1) 6.0 (5.0)
Median (Q1, Q3) 9.0 (5.0, 15.4) 10.8 (3.9, 13.5) 7.8 (3.9, 13.6) 5.5 (1.2, 9.2)
Mean age, y (SD) 65.8 (10.4) 64.8 (9.0) 63.7 (9.9) 67.9 (10.0)
Female, n (%) 21 (41.2) 22 (56.4) 17 (44.7) 3 (12.0)
Race, n (%)
Caucasian 50 (98.0) 39 (100.0) 37 (97.4) 23 (92.0)
Other 1 (2.0) 0 (0) 1 (2.6) 2 (8.0)
ECOG status, n (%)
0 18 (35.3) 4 (10.3) 5 (13.2) 6 (24.0)
1 25 (49.0) 20 (51.3) 14 (36.8) 8 (32.0)
2 8 (15.7) 15 (38.5) 19 (50.0) 11 (44.0)
Time since primary MM diagnosis (mo)
Mean (SD) 26.7 (36.0) 30.5 (40.8) 32.5 (39.2) 29.2 (49.6)
Median 10.7 13.2 13.0 8.7
Time since diagnosis of bone metastasis/lesion to enrolment (mo)
Mean (SD) 21.7 (32.3) 25.4 (41.3) 21.5 (37.6) 22.1 (44.3)
Median 4.1 5.8 1.6 3.7
History of SREsa, n 
(%)
30 (58.8) 25 (64.1) 31 (81.6) 11 (44.0)
Previous bisphos-
phonate useb, n 
(%)
42 (82.4) 19 (48.7) 19 (50.0) 22 (88.0)
Duration of previous bisphosphonate useb (mo)
Mean (SD) 20.1 (29.4) 22.2 (33.7) 28.8 (37.8) 23.1 (49.7)
Median (Q1, Q3) 2.9 (1.0, 32.2) 2.6 (0.4, 41.5) 3.2 (0.7, 52.7) 3.2 (1.1, 11.0)
ECOG, Eastern Cooperative Oncology Group; Q, quarter; MM, multiple myeloma; SD, standard de-
viation; SREs, skeletal- related events; UK, United Kingdom.
aPatients who experienced an SRE > 97 d before enrolment.
bPatients who received bisphosphonates before or at enrolment (more than 90 d prior to enrolment 
and within 90 d prior to enrolment).
TABLE  1 Baseline demographics and 
disease history
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There were some differences observed in the pattern of SREs 
between countries (Figure 1). In Spain and the UK, spinal cord com-
pression was reported more often (27.0% and 16.0%, respectively) 
than in Germany (2.8%) or Italy (4.5%). There were fewer reports of 
surgery to bone in Spain (7.9%) than in the other countries (range, 
18.6%- 19.7%). Vertebral fractures were reported less often in Italy 
(13.6%) than in the other countries (range, 13.8%- 23.3%). The fre-
quency of radiation to bone in the UK (25.6%) and Spain (23.8%) was 
around half of that reported in Germany (48.6%) and Italy (42.4%).
3.3 | Healthcare resource utilisation
3.3.1 | Inpatient stays
Overall, 103 of 281 patients experiencing SREs (36.7%) required 
hospitalisation. Although all types of SRE were associated with 
inpatient stays, the proportion requiring an inpatient stay varied 
considerably between SRE types (Figure 2). Overall, surgery to 
bone (72.3%), spinal cord compression (50.0%) and non- vertebral 
F IGURE  1 Number of SREs included in the HRU analysis, by country and by SRE type. VF and NVF are subsets of PF. HRU, healthcare 
resource utilisation; NVF, non- vertebral fracture; PF, pathologic fracture; RB, radiation to bone; SB, surgery to bone; SCC, spinal cord 
compression; SREs, skeletal- related events; UK, United Kingdom; VF, vertebral fracture
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fracture (46.2%) were most likely to require inpatient stays; radia-
tion to bone (14.0%) was the least likely. For certain types of SREs, 
the proportion requiring an inpatient stay also varied across coun-
tries (Figure 2).
Regarding duration of inpatient stay, data were collected 
for the first 100 SREs. All SREs were associated with substan-
tial lengths of inpatient stay (Figure 3A). The mean (SD) length of 
inpatient stay per SRE that required an inpatient stay was 20.6 
(22.9) days. Spinal cord compression required the longest mean 
(SD) stay per event (40.5 [40.8] days), while surgery to bone (14.6 
[19.4] days) and radiation to bone (15.9 [6.3] days) required the 
shortest stays per event. Across the four countries, the overall 
mean length of inpatient stay ranged from 16.5 to 25.5 days, with 
Germany having the shortest mean duration and Spain the longest 
(Figure 3B).
Across all SREs, the most common facility types for inpatient 
stays were surgical units/wards and oncology units/wards, with 
general units/wards, radiation units/wards and “other” units/
wards also used frequently (Table S1). Radiation to bone was most 
likely to be administered in an oncology unit/ward (mean [SD] 
length of stay, 13.2 [6.5] days). Patients with pathologic fracture 
or surgery to bone were most likely to be treated in a surgical 
unit/ward (mean [SD] length of stay, 16.9 [16.8] and 8.3 [4.5] days, 
respectively).
3.3.2 | Outpatient visits
Outpatient visits were also common across all SREs (Figure 4). 
Overall, 179 SREs (63.7%) required an outpatient visit, with 74.8% of 
radiation to bone events and 73.3% of vertebral fractures, compared 
with 50.0% of non- vertebral fracture events, requiring at least one 
visit. The pattern of outpatient visits was generally consistent across 
countries (Figure 4).
The overall mean (SD) number of outpatient visits per SRE was 
5.2 (7.1) (Figure S1). Radiation to bone was associated with the high-
est mean (SD) number of outpatient visits per SRE (8.9 [8.2] visits), 
with the number of visits required for other SREs ranging from 2.1 
(5.0) for surgery to bone to 3.9 (5.3) for vertebral fractures. There 
was some variation in the number of outpatient visits between coun-
tries (Figure S1).
3.3.3 | Procedures performed
External beam radiation therapy was the most common procedure 
type, with a mean of 4.3 (95% confidence interval [CI], 3.41- 5.10) 
procedures per SRE (Figure S2).
Overall, each SRE required a mean (SD) of 7.4 (6.9) proce-
dures (Figure 5). Radiation to bone and spinal cord compres-
sion were associated with the highest mean (SD) number of 
F IGURE  3 Mean duration of inpatient 
stay per SRE that required at least one 
inpatient stay (A) by SRE type and (B) 
by country. VF and NVF are subsets of 
PF. Data include only SREs requiring an 
inpatient stay. If an SRE contributed to 
multiple inpatient stays, the total duration 
of all of the inpatient stays was used. 
Error bars indicate SD. NVF, non- vertebral 
fracture; PF, pathologic fracture; Q, 
quarter; RB, radiation to bone; SB, surgery 
to bone; SCC, spinal cord compression; 
SD, standard deviation; SRE, skeletal- 
related event; UK, United Kingdom; VF, 
vertebral fracture
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procedures per SRE (11.4 [7.0] and 7.2 [6.6], respectively). 
There was some variation between countries (Figure 5). Most 
procedures were performed in an outpatient setting (5.1 [7.0] 
procedures per SRE); 2.1 (3.8) procedures per SRE required 
an overnight stay, with spinal cord compression most likely to 
require this.
3.3.4 | Emergency room and home health visits, and 
nursing home/long- term care facility stays
No home health visits were required, and very few emergency room 
visits (2 per 100 SREs) were reported. No nursing home/long- term 
facility care stays associated with SREs were reported.
F IGURE  4 Proportion of SREs requiring at least one outpatient visit, by country and by SRE type. VF and NVF are subsets of PF. NVF, 
non- vertebral fracture; PF, pathologic fracture; RB, radiation to bone; SB, surgery to bone; SCC, spinal cord compression; SRE, skeletal- 
related event; UK, United Kingdom; VF, vertebral fracture
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4  | DISCUSSION
To the best of our knowledge, this is the first prospective study to 
investigate HRU associated with SREs secondary to bone lesions 
in patients with MM in Europe. In addition, this is the first study 
in which HRU was assigned to specific SREs by the investigators. 
This ensured that HRU was included in the analysis only when it was 
considered, in the expert opinion of the investigators, to be directly 
related to the SRE and not to the underlying disease.
Patient characteristics at enrolment were broadly similar across 
the countries, although there was a tendency for better ECOG per-
formance status in Germany than in the other countries. Overall, 
radiation to bone (38.1%) and pathologic fracture (34.5%) were the 
most common SREs, and spinal cord compression was the least com-
mon (10.7%). In Spain and the UK, spinal cord compression was re-
ported considerably more often than in Germany and Italy; radiation 
to bone was reported about half as often. The proportion of patients 
who had previous treatment with bisphosphonates for the preven-
tion of SREs was approximately 50% in Italy and Spain and consider-
ably higher in Germany and the UK (over 80%). This variation could 
possibly reflect intercountry differences in patient management 
pathways; recruitment of patients in our study was according to pre-
defined targets and enrolment criteria and may not fully reflect the 
distribution of SREs in the real- world setting. Therefore, more stud-
ies would be required to verify such differences.
In line with studies of prostate cancer, breast cancer and lung 
cancer, all SREs were associated with substantial HRU.14-16 Inpatient 
stays were common (36.7% of SREs), at a rate similar to that pre-
viously reported for lung cancer (41.0%)15 and higher than that re-
ported for breast and prostate cancers (both 26.0%),14,16 with an 
average duration of stay of approximately 3 weeks. The reason for 
the differences in the proportions of SREs requiring an inpatient stay 
across tumour types cannot be firmly concluded from these analy-
ses, but it may be due to the high incidence of comorbidities in pa-
tients with MM; patients with MM are often immunocompromised, 
with an increased risk of severe infection, while 20%- 40% have renal 
impairment.17,18 Yet, interestingly, the proportion of patients with 
MM who discontinued the study (27.5%, primarily owing to death) 
was lower than for other cancer types: breast cancer, 36.3%; lung 
cancer, 69.6%; MM, 27.5%; and prostate cancer, 45.0% (data not 
published). These differences may reflect the longer survival times 
of patients with MM compared with patients with metastatic solid 
tumours and also any associated differences in disease status in 
these latter patients at the point of SRE development; for example, 
patients with prostate cancer were at an advanced stage,14 whereas 
patients with MM frequently have bone disease at diagnosis, earlier 
in the disease course.19
All SRE types were associated with hospitalisation and substan-
tial lengths of inpatient stay. Compared with other tumour subtypes 
included in this observational study, the proportion of patients 
with MM and SREs requiring an inpatient stay varied considerably 
across SRE types. Surgery to bone, spinal cord compression and 
non- vertebral fracture were most likely to require inpatient stays, 
and radiation to bone was the least likely. Spinal cord compression 
represents a significant burden because it often requires hospitalisa-
tion and, in this study, was associated with the longest duration of 
inpatient care (nearly 6 weeks). In patients with MM, 50% of spinal 
cord compressions required hospitalisation. This is a smaller pro-
portion than in patients with other cancer types (lung cancer, 80%; 
prostate cancer, 74%; breast cancer, 58%).14-16 The reasons for this 
difference are unclear and are beyond the scope of this study, but a 
speculative explanation could be that the threshold to initiate imag-
ing of the spine is much lower in patients with MM compared with 
other cancer types, possibly because there is great awareness of the 
propensity of MM to cause spinal cord compression. Indeed, such 
investigation is often a standard of care at diagnosis in patients with 
MM. Some between- country differences were noted in the dura-
tion of inpatient stay. Duration was longer in Italy and Spain than in 
Germany or the UK. Across all SREs, the most common facility types 
for inpatient stays were surgical units/wards and oncology units/
wards, with general units/wards, radiation units/wards and “other” 
units/wards also used frequently.
Outpatient visits were necessary for the majority of SREs 
(63.7%) and were most frequently required for radiation to bone 
(74.8%) and vertebral fracture (73.3%). In the UK, the mean num-
ber of outpatient visits required per SRE was less than one- third of 
that of the overall mean. This is probably owing to the fact that ra-
diotherapy is predominantly an outpatient procedure in the UK,20 
unless other medical requirements necessitate an inpatient stay. 
Nevertheless, the data presented here indicate that outpatient 
visits impose a considerable burden on healthcare resources in 
Europe, similar to findings reported for other cancer types in this 
study.3,14-16
This study has identified that almost every SRE required a pro-
cedure, and multiple procedures were common. Overall, a mean of 
7.4 procedures per SRE was required. Most procedures were per-
formed in an outpatient setting, and external beam radiation therapy 
was the most common type of procedure. Radiation to bone was 
associated with the highest number of procedures per SRE (11.4), 
which—coupled with the high number of outpatient visits for this 
procedure—makes it a major contributor to the burden that SREs 
place on healthcare systems. This is consistent with the findings of 
previous studies.21-23 The high numbers of outpatient visits and pro-
cedures observed probably reflect the use of multiple fractions of 
radiotherapy.16 Considering the differences in the characteristics of 
the patients enrolled, the relatively small sample size and any vari-
ations in clinical practices across the countries, overall, patterns of 
HRU were broadly consistent. However, in the UK, the numbers of 
outpatient visits, procedures overall and procedures per SRE were 
all substantially lower than in the other countries. Differences in 
clinical practice between the countries may help to explain this 
variation; for example, multiple- fraction radiation sessions are more 
commonplace in mainland Europe, while single- fraction radiation is 
used more often in the UK.14 Also in the UK, radiotherapy is not nec-
essarily available in all hospitals, so some patients may have to travel 
to alternative centres.20
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There are some limitations to this study, as previously reported 
by Hoefeler et al3 The differences in baseline characteristics be-
tween countries and physician clinical practice may explain some 
of the heterogeneity in outcomes. The duration of follow- up for 
this study was shorter than planned (median of 5.5- 10.8 months 
vs 18- 21 months) owing to slow recruitment (possibly because the 
trial was non- interventional) and early withdrawal from the study 
due to patient death. However, conclusions can still be drawn as 
the data showed a generally consistent approach to patient man-
agement across the countries. The numbers of patients enrolled 
per country were also limited, leading to small sample sizes in some 
SRE subsets. Some data were not accessible to investigators at all 
study sites (eg, home health visits). HRU for secondary SREs may 
have been assigned to a previous SRE; for example, HRU for spi-
nal cord compression may have been assigned to a previous patho-
logic fracture or radiation to bone. Thus, despite the known burden 
of this SRE, not all events were expected to be associated with an 
inpatient stay. It should also be noted that numbers of SRE types 
are not representative of the real- world distribution, because they 
are affected by the index SRE recruitment and the inclusion criteria 
(stating	that	patients	must	have	an	ECOG	status	≤	2	and	a	life	expec-
tancy	≥	6	months).	 These	 limitations,	 however,	would	be	 expected	
to result in an underestimation of the overall HRU associated with 
SREs; therefore, the true burden of SREs may be even greater than 
that suggested by these results.
Although data collection for this study commenced in 2007, the 
findings described here remain pertinent. It is likely that HRU result-
ing from the management of SREs in these patients has not changed 
significantly. While novel treatments are available, there is no evi-
dence that these treatments reduce the risk of SREs in patients, and 
their impact on HRU is currently unknown. Additionally, with more 
effective treatments for MM available which may result in an in-
creased life expectancy, patients may have a longer exposure to the 
risk of SREs. In these patients, non- drug- related costs (such as those 
resulting from bone complications) will remain a key cost driver. 
Therapies that preserve bone (eg, bisphosphonates or denosumab) 
and that help to reduce the incidence of SREs may have an important 
role to play in reducing the related HRU and the economic and clini-
cal burden associated with this disease. Bisphosphonates have been 
shown to reduce pathologic fractures, SREs and pain in patients with 
MM.24 In patients with bone lesions due to solid tumours (excluding 
breast or prostate cancers) or MM, denosumab was non- inferior to 
zoledronic acid in prolonging the time to first on- study SRE.25 In pa-
tients with newly diagnosed MM in a phase 3 study of denosumab 
(n = 859) and zoledronic acid (n = 859), denosumab was non- inferior 
to zoledronic acid (P = .01) in prolonging the time to first on- study 
SRE (hazards ratio [95% CI]: 0.98 [0.85- 1.14]).26
The timing of the initiation of treatment with agents that pre-
serve bone in patients with MM is an issue that should be considered. 
The International Myeloma Working Group (IMWG) recommends 
that bisphosphonates should be initiated in patients with MM, with 
or without detectable osteolytic bone lesions on conventional radi-
ography.27 The American Society of Clinical Oncology recommends 
that bone- targeted therapy should be considered in all patients 
with MM receiving first- line, antimyeloma therapy, regardless of the 
presence of osteolytic bone lesions on conventional radiography.27 
IMWG guidelines, published in 2017, for the optimal use of 18flu-
orodeoxyglucose positron emission tomography/computed tomog-
raphy (PET/CT) in patients with MM, recommend this technique to 
provide an earlier evaluation of response to therapy compared with 
MRI scans.28 It is therefore feasible that, with increased use of these 
imaging techniques to visualise the burden of myeloma disease, the 
number of patients who are eligible for treatment and hence the use 
of bone- preserving agents will increase and thus reduce the HRU 
associated with SREs in MM. The data reported here indicate that 
studies directly examining the impact of bisphosphonates and deno-
sumab on SRE- associated HRU would be warranted.
5  | CONCLUSIONS
SREs secondary to bone lesions are frequently observed in patients 
with MM, with radiation to the bone and pathologic fracture being 
the most common. This study highlights that SREs in these patients 
are associated with substantial HRU across the four European coun-
tries. All types of SRE were associated with hospitalisation, multiple 
procedures and substantial periods of inpatient stay. Mean inpa-
tient stay was shortest in Germany where both the proportion of 
patients with ECOG performance status of 2 and incidence of spinal 
cord compression were lowest. This is in addition to the impact that 
SREs have on patients’ well- being, activities of daily life and abil-
ity to work. Initiating treatments that delay or prevent SREs will, 
therefore, help not only to reduce the healthcare burden and reduce 
costs, particularly associated with inpatient stay, but also to have a 
positive effect on the quality of life of patients. Consequently, phy-
sicians involved in the management of MM should initiate prompt 
treatment with agents that preserve bone.
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